Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Nasopharyngeal Carcinoma 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Virus Diseases 1Urethral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Liver Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Camurati-Engelmann Syndrome × Gemcitabine × Clear all
NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

EMD Serono

Phase 2/3 Terminated
309 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡